{"id":667943,"date":"2023-09-14T19:04:01","date_gmt":"2023-09-14T19:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667943"},"modified":"2023-09-14T19:04:01","modified_gmt":"2023-09-14T19:04:01","slug":"alkpositive-nonsmall-cell-lung-cancer-alk-nsclc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-akeso-takeda-pfizer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alkpositive-nonsmall-cell-lung-cancer-alk-nsclc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-akeso-takeda-pfizer_667943.html","title":{"rendered":"ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akeso, Takeda, Pfizer"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akeso, Takeda, Pfizer\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akeso, Takeda, Pfizer\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the ALK-positive Non-Small Cell Lung Cancer Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The ALK-positive Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial, regulatory, and ALK-positive Non-Small Cell Lung Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging ALK-positive Non-Small Cell Lung Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging<strong> therapies for ALK-positive Non-Small Cell Lung Cancer treatment<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different <strong>ALK-positive Non-Small Cell Lung Cancer therapies<\/strong> segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major <strong>ALK-positive Non-Small Cell Lung Cancer companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the <strong>ALK-positive Non-Small Cell Lung Cancer drugs<\/strong> that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>ALK-positive Non-Small Cell Lung Cancer therapeutics market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/098bad3d650f79a2e4781445c064d5ef.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Anaplastic Lymphoma Kinase (ALK), is a CD receptor (CD246) that plays a significant role in the development of neurons. The ALK gene products are known to promote cell growth\/proliferation and inhibit apoptosis at baseline. There are several therapies approved under this category, such as ALUNBRIG (brigatinib), ZYKADIA (ceritinib), XALKORI (crizotinib), and ALECTINIB. Apart from this, LORBRENA (lorlatinib) is another therapy available for the ALK-positive NSCLC patient pool.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx. 30+ key companies developing the therapies for ALK-positive Non-Small Cell Lung Cancer. Currently,&nbsp; Betta Pharmaceuticals\/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, and Pfizer are among the key pharma and biotech giants leading the ALK-positive Non-Small Cell Lung Cancer therapeutics landscape with their drug candidates in the mid to advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">F. Hoffmann-La Roche Ltd.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Suzhou Zelgen Biopharmaceuticals Co., Ltd<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ariad Pharmaceutica<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chia Tai Tianqing Pharmaceutical Group<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Akeso<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Ensartinib: Betta Pharmaceuticals\/Xcovery<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)&ndash;positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1\/2 trial.&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>TQ-B3139 &#8211; Chia Tai Tianqing Pharmaceutical Group<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and ALK-positive Non-Small Cell Lung Cancer Companies Working in the Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging ALK-positive Non-Small Cell Lung Cancer Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intramuscular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intratumoral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bispecific antibodies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunotherapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal antibodies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecules<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the ALK-positive Non-Small Cell Lung Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. ALK-positive Non-Small Cell Lung Cancer Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. ALK-positive Non-Small Cell Lung Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. ALK-positive Non-Small Cell Lung Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. ALK-positive Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. ALK-positive Non-Small Cell Lung Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. ALK-positive Non-Small Cell Lung Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. ALK-positive Non-Small Cell Lung Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major ALK-positive Non-Small Cell Lung Cancer Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the ALK-positive Non-Small Cell Lung Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. ALK-positive Non-Small Cell Lung Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. ALK-positive Non-Small Cell Lung Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. ALK-positive Non-Small Cell Lung Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" class=\"h5 post__title entry-title\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-market\" target=\"_blank\">Diabetes Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Diabetes Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diabetes market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alkpositive-nonsmall-cell-lung-cancer-alk-nsclc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-akeso-takeda-pfizer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/oncology\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/oncology<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/oncology\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alkpositive-nonsmall-cell-lung-cancer-alk-nsclc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-akeso-takeda-pfizer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) therapeutics landscape based on different Routes of Administration (ROA), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alkpositive-nonsmall-cell-lung-cancer-alk-nsclc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-akeso-takeda-pfizer_667943.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-667943","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=667943"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=667943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=667943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=667943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}